Last viewed:
INBX
Prices are updated after-hours
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
(0.0% 1d)
(-2.3% 1m)
(70.8% 1y)
(0.0% 2d)
(0.1% 3d)
(-0.6% 7d)
(-23.39%
volume)
Earnings Calendar: 2024-03-04
Market Cap: $ 1,629,589,290
http://www.inhibrx.com
Sec
Filling
|
Patents
| 95 employees
Inhibrx, Inc. engages in researching and developing biotechnology. It is a clinical stage company, which focuses on developing pipeline of novel biologic therapeutic candidates. The firm’s pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
infectious disease
add to watch list
Paper trade
email alert is off
Press-releases
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX
Published: 2024-03-26
(Crawled : 00:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
-2.18%
480
|
Health Technology
| -5.71%
| O: -0.26%
H: 0.0%
C: 0.0%
TGAN
|
$4.83
-0.41%
-0.41%
200K
|
Manufacturing
| -1.02%
| O: 0.2%
H: 0.0%
C: -0.2%
FREE
|
$4.815
-0.1%
-0.1%
180K
|
Consumer Non-Durables
| 0.0%
| O: 0.0%
H: 0.21%
C: 0.0%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -4.35%
| O: 1.06%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| -2.68%
| O: 0.29%
H: 0.23%
C: -0.06%
HMST
|
$12.2
-5.94%
-6.31%
170K
|
Finance
| -15.23%
| O: 0.26%
H: 0.07%
C: -0.85%
EVBG
|
$34.9
0.0%
580K
|
Technology Services
| 0.32%
| O: 0.09%
H: 0.03%
C: -0.03%
INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - INBX, KAMN, JNPR, HAYN
Published: 2024-03-12
(Crawled : 03:00)
- prnewswire.com
JNPR
|
$35.36
-1.45%
0.0%
5.3M
|
Technology Services
| -3.03%
| O: 0.38%
H: 0.08%
C: -0.78%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -2.64%
| O: 0.01%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| -2.93%
| O: 0.26%
H: 0.21%
C: -0.03%
HAYN
|
$60.38
-0.15%
-0.15%
140K
|
Non-Energy Minerals
| 1.77%
| O: -0.03%
H: 0.19%
C: 0.0%
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Published: 2024-02-28
(Crawled : 19:00)
- biospace.com/
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -2.67%
| O: -0.63%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| -13.73%
| O: -0.86%
H: 0.13%
C: -5.66%
year
financial
results
Acadia Announces Additions to Executive Team - Jan 31, 2024
Published: 2024-01-31
(Crawled : 10:00)
- biospace.com/
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| -11.92%
| O: -0.36%
H: 0.57%
C: -0.21%
EXEL
|
$23.7
1.76%
1.73%
1.5M
|
Health Technology
| 6.4%
| O: 0.18%
H: 0.55%
C: -0.78%
ACAD
|
News
|
$16.57
-1.02%
-1.03%
1.3M
|
Health Technology
| -37.61%
| O: -0.71%
H: 0.71%
C: -2.74%
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi
Published: 2024-01-23
(Crawled : 17:00)
- prnewswire.com
NS
6
d
|
$22.55
-0.71%
0.0%
630K
|
Distribution Services
| 6.52%
| O: -0.09%
H: 0.47%
C: -1.22%
ADM
|
$61.56
-0.37%
-0.6%
3.7M
|
Process Industries
| 19.54%
| O: 1.04%
H: 3.75%
C: 0.15%
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -7.96%
| O: -2.05%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 2.4%
| O: 6.51%
H: 4.73%
C: 2.25%
sanofi
Press Release: Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Published: 2024-01-23
(Crawled : 07:00)
- globenewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -7.96%
| O: -2.05%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 2.4%
| O: 6.51%
H: 4.73%
C: 2.25%
rare
disease
pipeline
acquire
potential
sanofi
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
Published: 2024-01-23
(Crawled : 06:00)
- prnewswire.com
SNY
|
News
|
$46.66
-2.16%
-2.21%
1.7M
|
Health Technology
| -7.96%
| O: -2.05%
H: 0.0%
C: 0.0%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 2.4%
| O: 6.51%
H: 4.73%
C: 2.25%
inbrx-101
sanofi
Navigating the Complex Market Landscape of Rare Genetic Disorders: A Deep Dive into Hereditary Angioedema, Wilson Disease, Menkes Disease, and Alpha-1 Antitrypsin Deficiency (AATD) | DelveInsight
Published: 2023-11-09
(Crawled : 22:00)
- prnewswire.com
ATXS
|
$9.02
-6.43%
-6.87%
660K
|
Manufacturing
| 107.76%
| O: 0.43%
H: 0.86%
C: -1.29%
OPK
|
$1.225
-2.0%
-2.04%
6.1M
|
Health Technology
| -2.34%
| O: 1.56%
H: 0.0%
C: -3.08%
IONS
|
$42.455
1.47%
1.45%
730K
|
Health Technology
| -11.56%
| O: 0.53%
H: 0.38%
C: -2.52%
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 86.5%
| O: 0.98%
H: 5.52%
C: 3.35%
INCY
|
$51.72
0.14%
0.14%
1.5M
|
Health Technology
| -1.66%
| O: 0.4%
H: 0.0%
C: -0.55%
rare
genetic
market
Inhibrx Announces Participation in Upcoming Scientific Conferences
Published: 2023-10-18
(Crawled : 20:00)
- prnewswire.com
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 99.01%
| O: 0.17%
H: 0.0%
C: -7.97%
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
Published: 2023-09-19
(Crawled : 20:00)
- prnewswire.com
INBX
|
$34.385
0.75%
0.74%
220K
|
Health Technology
| 64.48%
| O: -0.1%
H: 2.75%
C: -5.69%
inbrx-101
treatment
canada
See all
Last 15 days Sec forms
File Id
Form
Published Date
Transaction Date
Direction
Code
Amount Transacted
Owned Amount
0001739614-24-000019
4
2024-03-22
2024-03-22
Sell
M
110
18020
0001739614-24-000019
4
2024-03-22
2024-03-21
Sell
M
3113
18130
0001739614-24-000019
4
2024-03-22
2024-03-20
Sell
M
16777
21243